Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis (EXEL) with a Peer Perform rating and no price target Zanzalintinib is unlikely to fully replenish cabozantinib’s potential lost revenues, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: